Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3×CD20) in Japanese Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A Phase 1/2, Open-Label, Dose-Escalation Trial With Expansion Cohorts

X
Trial Profile

Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3×CD20) in Japanese Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A Phase 1/2, Open-Label, Dose-Escalation Trial With Expansion Cohorts

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Epcoritamab (Primary)
  • Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms EPCORE™ NHL-3
  • Sponsors AbbVie; Genmab
  • Most Recent Events

    • 12 Dec 2023 Results of a population pharmacokinetic (PK) model based analysis using data from 2 phase 1/2 clinical trials (EPCORE NHL-1 [NCT03625037] and EPCORE NHL-3 [NCT04542824]) evaluating epcoritamab in patients with R/R B cell non Hodgkin lymphoma (B NHL), at the 65th American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2023 Results of pooled analysis(cutoff of Jan 31, 2022) from phase 1/2 EPCORE NHL-1 (NCT03625037) and EPCORE NHL-3 (NCT04542824) trials presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 01 Dec 2023 Results (As of January 31, 2022, n=36) assessing safety and efficacy of epcoritamab monotherapy in Japanese patients with R/R CD20+ B-cell non-Hodgkins lymphoma published in the Cancer Science
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top